ONESOURCE SPECIALTY PHARMA Financial Statement Analysis
|
||
|
The Revenues of ONESOURCE SPECIALTY PHARMA have increased by 655.93% YoY .
The Earnings Per Share (EPS) of ONESOURCE SPECIALTY PHARMA has increased by Positive YoY. |
||
ONESOURCE SPECIALTY PHARMA Last 5 Annual Financial Results
[BOM: 544292|NSE : ONESOURCE]
| Standalone | Mar2025 | Mar2024 | Mar2023 |
|---|---|---|---|
| Revenues | ₹1,300 Cr | ₹172 Cr | ₹39 Cr |
| Expenses | ₹932 Cr | ₹259 Cr | ₹199 Cr |
| Operating Profit (Excl OI) | ₹367 Cr | ₹-88 Cr | ₹-161 Cr |
| Other Income | ₹20 Cr | ₹4.23 Cr | ₹2.70 Cr |
| Interest | ₹162 Cr | ₹89 Cr | ₹48 Cr |
| Depreciation | ₹135 Cr | ₹76 Cr | ₹66 Cr |
| Profit Before Tax | ₹-21 Cr | ₹-365 Cr | ₹-430 Cr |
| Profit After Tax | ₹20 Cr | ₹-365 Cr | ₹-430 Cr |
| Earnings Per Share (Rs) | ₹1.75 | ₹-91.01 | ₹-107.12 |
| PAT Margin (%) | 1.53 | -212.27 | -1,109.56 |
| ROE(%) | 0.64 | -62.35 | -55.02 |
| ROCE(%) | 3.66 | -21.34 | -23.53 |
| Total Debt/Equity(x) | 0.13 | 1.44 | 1.07 |
Key Financials |
||
| Market Cap | : | ₹ 16,089.3 Cr |
| Revenue (TTM) | : | ₹ 1,463.8 Cr |
| Net Profit(TTM) | : | ₹ 174.6 Cr |
| EPS (TTM) | : | ₹ 15.2 |
| P/E (TTM) | : | 92.1 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| ONESOURCE SPECIALTY PHARMA | 3.4% | 4.3% | -16.5% |
| SUN PHARMACEUTICAL INDUSTRIES | -5.6% | -2.5% | -1.7% |
| DIVIS LABORATORIES | -2.6% | -8.7% | 1.2% |
| CIPLA | -4.1% | -11.5% | -19% |
| TORRENT PHARMACEUTICALS | -7.2% | -8% | 27.6% |
| DR REDDYS LABORATORIES | -6.5% | -5.4% | 3.9% |
| MANKIND PHARMA | -1.1% | -11.1% | -16.9% |
| ZYDUS LIFESCIENCES | -4.4% | -6.3% | -4.8% |
| LUPIN | -3% | -1.1% | 10.5% |
ONESOURCE SPECIALTY PHARMA Revenues
[BOM: 544292|NSE : ONESOURCE]
| Y-o-Y | 655.93 % |
| 5 Yr CAGR | 479.39 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2025 | ₹1,300 Cr | 655.93 | |
| Mar2024 | ₹172 Cr | 344.07 | |
| Mar2023 | ₹39 Cr | - | |
ONESOURCE SPECIALTY PHARMA Operating Profit
[BOM: 544292|NSE : ONESOURCE]
| Y-o-Y | Positive |
| 5 Yr CAGR | Positive |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2025 | ₹367 Cr | Positive | |
| Mar2024 | ₹-88 Cr | Negative | |
| Mar2023 | ₹-161 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | Positive |
| 5 Yr CAGR | Positive |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2025 | 28.26% | Positive | |
| Mar2024 | -50.91% | Negative | |
| Mar2023 | -414.89% | - | |
ONESOURCE SPECIALTY PHARMA Profit After Tax
[BOM: 544292|NSE : ONESOURCE]
| Y-o-Y | Positive |
| 5 Yr CAGR | Positive |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2025 | ₹20 Cr | Positive | |
| Mar2024 | ₹-365 Cr | Negative | |
| Mar2023 | ₹-430 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | Positive |
| 5 Yr CAGR | Positive |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2025 | 1.53 % | Positive | |
| Mar2024 | -212.27 % | Negative | |
| Mar2023 | -1109.56 % | - | |
ONESOURCE SPECIALTY PHARMA Earnings Per Share (EPS)
[BOM: 544292|NSE : ONESOURCE]
| Y-o-Y | Positive |
| 5 Yr CAGR | Positive |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2025 | ₹1.75 | Positive | |
| Mar2024 | ₹-91 | Negative | |
| Mar2023 | ₹-107 | - | |
ONESOURCE SPECIALTY PHARMA Return on Capital Employed (ROCE)
[BOM: 544292|NSE : ONESOURCE]
| Y-o-Y | Positive |
| 5 Yr CAGR | Positive |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2025 | 3.66% | Positive | |
| Mar2024 | -21.34% | Negative | |
| Mar2023 | -23.53% | - | |
ONESOURCE SPECIALTY PHARMA Share Price vs Sensex
| Current Share Price | : | ₹1,404.0 |
| Current MarketCap | : | ₹ 16,089.3 Cr |
| Updated EOD on | : | Apr 02,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ONESOURCE SPECIALTY PHARMA | 3.4% |
4.3% |
-16.5% |
| SENSEX | -1% |
-10.9% |
-6% |
ONESOURCE SPECIALTY PHARMA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | 6.4% | 8.9% | 7.5% |
| BSE MIDSMALLCAP | 4.7% | 9% | 8.4% |
| BSE 250 SMALLCAP INDEX | 1.4% | -8% | -4.1% |
| BSE 400 MIDSMALLCAP INDEX | 0.1% | -9.4% | -1.2% |
| BSE 500 | -0.5% | -10.6% | -2.7% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY SMALLCAP 250 | 1% | -8.2% | -3% |
| NIFTY 500 EQUAL WEIGHT | 0.4% | -9.3% | -1.4% |
| NIFTY MIDSMALL HEALTHCARE | 0.4% | -5.9% | 1.1% |
| NIFTY MIDSMALLCAP 400 | -0.1% | -9.6% | 0.9% |
| NIFTY500 LARGEMIDSMALL EQUAL-CAP WEIGHTED INDEX | -0.1% | -9.9% | -1.1% |
You may also like the below Video Courses
FAQ about ONESOURCE SPECIALTY PHARMA Financials
How the annual revenues of ONESOURCE SPECIALTY PHARMA have changed ?
The Revenues of ONESOURCE SPECIALTY PHARMA have increased by 655.93% YoY .
How the Earnings per Share (EPS) of ONESOURCE SPECIALTY PHARMA have changed?
The Earnings Per Share (EPS) of ONESOURCE SPECIALTY PHARMA has increased by Positive YoY .
Check out Intrinsic Value of Peers of ONESOURCE SPECIALTY PHARMA
Compare Stock Analytics of Peers of ONESOURCE SPECIALTY PHARMA
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
